2023 World Conference on Lung Cancer (Posters)-EP13.07. Is Concept of Continuous Immunotherapy Beyond Progression Effective in Small Cell Lung Cancer?

EP13.07. Is Concept of Continuous Immunotherapy Beyond Progression Effective in Small Cell Lung Cancer? - PDF(Abstract)

Pdf Summary

This study aimed to investigate whether continuous immunotherapy beyond progression is effective in small cell lung cancer (SCLC). The researchers retrospectively reviewed medical records of SCLC patients treated with chemo-immunotherapy at their hospital. The study included 36 patients with a median age of 73. Overall, 66.7% of patients had a positive response to treatment, and the disease control rate was 86.1%. The median progression-free survival (PFS) and time to treatment failure (TTF) were 5.1 and 10.3 months, respectively. The median overall survival (OS) was 13.6 months. <br /><br />Of the patients, 39% received immunotherapy beyond progression. Some patients were treated with chemo-immunotherapy and local ablative radiotherapy, some with chemo-immunotherapy alone, some with local ablative radiotherapy alone, and some with continuous immunotherapy alone. In these patients, the PFS, TTF, and OS were 6.7, 21.4, and 39.3 months, respectively. The median cycle of immunotherapy in these patients was 16 months. Notably, TTF exceeded 12 months in 86% of these cases.<br /><br />The findings suggest that continuous immunotherapy beyond progression could be effective in SCLC and may provide a favorable prognosis in selected cases. This concept challenges the previous perception of SCLC as an aggressive malignancy with poor clinical outcomes. The study highlights the potential of immunotherapy as a treatment strategy for SCLC and suggests that further investigation is warranted.

Asset Subtitle

Ken Yamamoto

Meta Tag

Speaker Ken Yamamoto

Topic SCLC & Neuroendocrine Tumors: Relapse & Salvage Therapy

Keywords

continuous immunotherapy

small cell lung cancer

SCLC

chemo-immunotherapy

medical records

positive response

disease control rate

progression-free survival

time to treatment failure

overall survival